Logo

BioFactura Initiates P-I Study of BFI-751 (biosimilar- ustekinumab)

Share this

BioFactura Initiates P-I Study of BFI-751 (biosimilar- ustekinumab)

Shots:

  • The company initiates the P-I study to evaluate the safety and tolerability of BFI-751 vs in 210 healthy volunteers and their immune response across Australia and New Zealand
  • The 1EPs of the study is to compare the PK of 751-BFI to the US & EU-Stelara following a single dose under the skin
  • BFI-751 is a biosimilar drug referencing Stelara- indicated to treat CD- UC- PsO and PsA

to Ref: Prweb | Image: LinkedIn

Click here to­ read the full press release 

Senior Editor

This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com

Share this article on WhatsApp, LinkedIn and Twitter

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions